CTRI/2022/12/048590尚未招募3 期
A TRIPLE-BLIND RANDOMIZED STUDY TO COMPARE THE EFFECTS OF PLATELET RICH PLASMA VERSUS GROWTH FACTOR CONCENTRATE IN PATIENTS OF OSTEOARTHRITIS KNEE
Teerthanker mahaveer medical college and research centre0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with OA knees grade II, III according to Kellgren and Lawrence system.
- •-Patients who are satisfying the ACR criteria for diagnosis of osteoarthritis knee.
排除标准
- •a) Any malignancy.
- •b) Drug Abuse
- •c) Gouty Arthritis /inflammatory arthritis
- •d) Active knee infection.
- •e) Patient Suffering from Anemia, Bleeding, Disorders of Rheumatoid Arthritis
- •f) Genu varum/valgum >5 degree
- •g) Uncontrolled Diabetes Mellitus
- •h) Ligamentous instability of knee (Tested by Clinical examination)
- •i) osteoarthritis of any other joint
研究者
相似试验
进行中（未招募）
不适用
A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION. - NDEUCTR2007-004938-16-ITAstellas Pharma Europe B.V.
已完成
2 期
COMPARISON OF TWO TYPES OF NERVE BLOCKS USING ULTRASOUND GUIDANCE FOR PATIENTS WITH FEMUR FRACTURECTRI/2021/05/033329BHARATI VIDYAPEETH HOSPITAL AND RESEARCH CENTRE60
进行中（未招募）
不适用
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment withDenosumab versus Alendronate Sodium in Postmenopausal Women with LowBone Mineral DensityPostmenopausal osteoporosis /osteopeniaEUCTR2005-005081-37-DEAmgen Inc1,100
进行中（未招募）
不适用
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment withDenosumab versus Alendronate Sodium in Postmenopausal Women with LowBone Mineral DensityPostmenopausal osteoporosis /osteopeniaEUCTR2005-005081-37-BEAmgen Inc1,100
进行中（未招募）
不适用
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment withDenosumab versus Alendronate Sodium in Postmenopausal Women with LowBone Mineral DensityPostmenopausal osteoporosis /osteopeniaEUCTR2005-005081-37-DKAmgen Inc1,100